Formycon raises H1 2026 revenue forecast, narrows losses

Formycon SE (ETR: FYB) updated its financial outlook for the first half of 2026, projecting higher revenue and a narrower net loss compared with prior expectations.

The German biotechnology company, which specializes in ophthalmology treatments, now expects H1 2026 revenue to exceed initial guidance. While specific figures were not disclosed, management attributed the upward revision to robust demand for its pipeline products, including biosimilars targeting eye diseases.

Formycon also reported a reduction in its net loss for the period, narrowing the deficit from previous estimates. The company did not provide exact loss figures but emphasized improved operational efficiency and sustained market adoption of its therapies as key drivers behind the better-than-expected performance.

Analysts noted that Formycon’s updated guidance reflects growing investor confidence in its biosimilar portfolio, particularly in niche therapeutic areas where competition remains limited. The company’s focus on ophthalmology has positioned it as a niche player in Europe’s biotech sector, where pipeline visibility and regulatory milestones often influence stock performance.

Shares of Formycon were indicated higher in pre-market trading following the update, though the company did not comment on stock-specific movements.